Record Q2 revenue and margin were driven by robust Amtagvi demand, expanding ATC network, and operational efficiencies. Pipeline advanced with key regulatory milestones and international approvals, while strong cash reserves support ongoing growth and R&D.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.